Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Comment by Hoover69on Sep 20, 2023 9:26am
55 Views
Post# 35645006

RE:Pharma Profits have kicked in!!!!!!!!!!!!! 3 P's, Pidduck,

RE:Pharma Profits have kicked in!!!!!!!!!!!!! 3 P's, Pidduck, Great you had a five bagger on Chrysler.  Well done.  Your numbers earlier suggest a 625 bagger for LABS - not going to happen.  
subaru1i wrote: Profit margins, Product mix.   From today's press release first:

MediPharm has made significant improvement in its adjusted gross margin. In the last reported quarter, Q2 2023, this was approximately 21% vs negative 1% in Q2 2022.

Now let me take the time and detail to explain to younger investors with a personal career real life example.   

The profit margins in the recreatonal pot world are RAZOR thin to the point as Mr. Pidduck brought up at the last CC that some recreational cannabis companies have delayed paying their excise tax trying to stay afloat as a company.   The profit margins in the world of cannabinoid pharmaceutical molecules are much healthier.  Medipharm Labs does not have a magic wand and is able to generate profits margins of 21% strictly in the recreational segment when others, even the largest, are struggling to achieve profitability in the recreational segment.   That statement in today's press release by Pidduck on Profit margins has to do with Product mix.  Product mix being the difference in profit margins generated by the recreational segment vs the pharmaceutical segment.  

Now for a real world example:

In the mid 1990's, say 1994, Chrylser was producing the Dodge Neon, capable of manufacturing around 200,000 of those vehicles per year.   Let this represent the recreational pot segment.   Profit margins on that vehicle were RAZOR thin, less than $1,500 USD per vehicle.  We had to beat up our suppliers quite severely in order just to achieve that margin.   In Detroit however at the Jefferson Assembly Plant, we were also building the new Jeep Grand Cherokee and between entry level and high optioned vehicles in that line, the average profit margin per vehicle was $15,000 per vehicle and on an an apples to apples volume basis, 200,000 Jeep G.C.'s yielded $3 billion in profits while the Neon generated only $300 million in profits.  

So it's the product mix that shifted the profit margins for Chrysler and so too pharmacuetical API sales is what shifted the profited margins for LABS from -1% to +22%.  That is a HUGE, MASSIVE shift in profit margins.  

Oh, what did I do when I saw those profit margins on the new Jeep?  Well Chrysler stock was sitting at around $5 or $6 bucks so I bought as much as possible and simply had to wait for the earnings numbers to come out because of those massive profit margins on the new Jeep.   I sold at over $30.

When you see a massive shift in profit margins like Mr. Pidduck told us AGAIN today, you have to ask yourself as an investor, what has changed and sharing life experience I'm giving you the answer.  Whether you buy more LABS or not, that's your business.   






<< Previous
Bullboard Posts
Next >>